Importantly, primary patient-derived CLL cells showed high sensitivity to dinaciclib + ABT-737 or ABT-199, as indicated by cell viability analyses with Annexin V-PI and flow cytometry (Figure 7A and 7B). Here, ANXA5 is linked to B-cell chronic lymphocytic leukemia.